Finance

Lists
A1RG34:BVMF
Argenx Se Bdr
220,00 BRL
0,00%
(0,00) 1D
18-ноя., 13:33:57 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1RG34...
Mkt. cap
59,48 млд
Avg. vol.
52,00
Volume
0,00
52-wk high
222,17 BRL
52-wk low
143,22 BRL
Shares outstanding
62,89 млн
No. of employees
2 миң
Mkt. cap
59,48 млд
Avg. vol.
52,00
Volume
0,00
52-wk high
222,17 BRL
52-wk low
143,22 BRL
Shares outstanding
62,89 млн
No. of employees
2 миң
News stories
From web sources and news partners
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About Argenx Se Bdr
CEO-
Employees1,86 миң
Founded2008-ж., 25-апр.
Headquarters-
SectorHealth Care
Industry-
Websiteargenx.com
Last report
2026-ж., 22-окт.
Fiscal period
Q3 2026
7,80 USD / -27,83 USD
+128,03%beat
Revenue / Est. (USD)
1,75 млд / 1,64 млд
+7,03%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
1,31 млд
1,31 млд
1,54 млд
1,75 млд
Cost of goods sold
521,40 млн
564,00 млн
631,00 млн
668,00 млн
Cost of revenue
521,40 млн
564,00 млн
631,00 млн
668,00 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
429,62 млн
355,00 млн
417,00 млн
448,00 млн
Operating expense
429,62 млн
355,00 млн
417,00 млн
448,00 млн
Total operating expenses
951,02 млн
919,00 млн
1,05 млд
1,12 млд
Operating income
359,56 млн
394,00 млн
493,00 млн
635,00 млн
Other non operating income
-907,00 миң
-
-1,00 млн
1,00 млн
EBT including unusual items
403,29 млн
426,00 млн
531,00 млн
538,00 млн
EBT excluding unusual items
391,71 млн
426,00 млн
531,00 млн
688,00 млн
Income tax expense
-129,66 млн
60,00 млн
59,00 млн
32,00 млн
Effective tax rate
-32,15%
14,08%
11,11%
5,95%
Other operating expenses
-
-
-
-
Net income
532,95 млн
366,00 млн
472,00 млн
506,00 млн
Net profit margin
40,67%
27,88%
30,63%
28,90%
Earnings per share
8,02
5,52
7,32
7,80
Interest and investment income
44,95 млн
44,00 млн
48,00 млн
45,00 млн
Interest expense
-
-1,00 млн
-1,00 млн
-1,00 млн
Net interest expenses
44,95 млн
43,00 млн
47,00 млн
44,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
361,38 млн
395,82 млн
501,50 млн
636,82 млн
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору